Antiviral Drugs Market to Exhibit 3.2% CAGR till 2026; Rising Incidence of Viral Diseases to Fuel Growth

The global antiviral drugs market size is projected to reach USD 44.2 billion by 2026. It is set to gain traction from the rising prevalence of viral diseases. According to the Centers for Disease Control and Prevention, in the U.S., approximately 125,000 to 200,000 infections occur annually. Out of this, around 70% of the adults are symptomatic. Fortune Business Insights™ provided this information in a recently published report, titled, “Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026.” The report further states that the market stood at USD 36.1 billion in 2018. However, it would exhibit a CAGR of 3.2% during the forecast period from 2019 to 2026.

ViiV Healthcare Submits New Drug Application to the FDA for Fostemsavir

In December 2019, ViiV Healthcare, a pharmaceutical company jointly owned by Pfizer and GlaxoSmithKline, announced its successful submission of a New Drug Application (NDA) to the FDA. It was mainly done to seek approval for the company’s first-in-class, investigational attachment inhibitor called fostemsavir. It is meant for the treatment of HIV-1 infection. It will be combined with other antiretroviral agents in adults with multidrug-resistant HIV-1. They must be treatment-experienced and must not be capable of forming a suppressive regimen because of safety, intolerance, and resistance considerations.

The company officials declared that antiretroviral medicines can prove to be very efficient in suppressing HIV and thereby, reduce AIDS-related deaths, HIV transmission, and disease progression. However, HIV can change persistently and because of this, a few patients may develop resistance to antiretroviral medicines. Hence, their treatment regimens would eventually fail. But the new drug will be a vital treatment option for those affected by HIV and those who cannot suppress the virus with other medicines.  

To Get the detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/antiviral-drugs-market-102190

Rising Number of Unique Product Launches to Boost Growth

The market consists of numerous pharmaceutical giants that are constantly participating in the research and development of antiviral agents. It is giving rise to the launch of numerous blockbuster drugs. Triumeq by GlaxoSmithKline and Biktarvy by Gilead Science, for instance, are gradually changing the sphere of antiretroviral therapy. In addition to that, upsurging uptake of similar agents and enhanced distribution by the manufacturers would augment the antiviral market growth during the forecast period.

Key Players Aim to Bag FDA Approvals to Expand Product Portfolio

Gilead Sciences, an American biotechnology company based in Foster City, dominated the market because of the high sales of its drugs, namely, Harvoni and Biktarvy. In 2018, The company’s drug Genvoya, a combination of tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir, procured USD 4.5 billion in terms of revenue. Overall, companies are trying to bag FDA approval for their new products to increase sales. They are also keeping up with the latest antiviral drugs market trends. Below are a couple of the latest industry developments:

• April 2019: Gilead Sciences submitted a supplemental New Drug Application (sNDA) to the FDA for once-daily Descovy for HIV pre-exposure prophylaxis.


• August 2017: AbbVie announced that the FDA has granted approval of MAVYRET, a prescription medicine used to treat children and adults with chronic hepatitis C virus.

Fortune Business Insights™ lists out some of the most renowned organizations operating in the antiviral drugs market. They are as follows:

• Merck & Co., Inc.


• Abbvie, Inc.


• Novartis AG


• Gilead Sciences


• Mylan N.V.


• Bristol-Myers Squibb Company


• GlaxoSmithKline


• Janssen Pharmaceuticals, Inc.


• Other key market players

Further Report Findings-

• North America acquired USD 13.9 billion in 2018 in terms of antiviral drugs market revenue owing to the rising prevalence of HIV in this region.


• Asia Pacific is likely to exhibit a high CAGR backed by the established pharmaceutical industry in the emerging countries, such as Japan and India.


• The governments of Mexico and Brazil in Latin America are taking initiatives to manage viral infections, which, in turn, is contribute to the growth of this region.


• The protease inhibitors segment under the drug class criterion held 13.7% antiviral drugs market share in 2018.


• Increasing prevalence of influenza would propel the growth of market in the near future.

The antiviral drugs market can be segmented on the bases of: